Nevolat (Liraglutide)

Liraglutide mimics the natural hormone GLP‑1, binding to its receptor on pancreatic beta cells to increase insulin secretion only when glucose levels are high. It simultaneously suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways, aiding glycaemic control and weight loss.

The dose of Nevolat is individualized by the prescribing healthcare professional. Initiation typically starts with a low dose that is gradually increased based on tolerability and therapeutic response, following the prescriber’s clinical judgment and local labeling.

Safety data for liraglutide during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Nevolat, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nevolat (liraglutide) shares the class‑wide mechanisms of GLP‑1 agonists but differs in dosing frequency and clinical trial data. Unlike weekly agents such as semaglutide, liraglutide is administered daily, offering more flexible titration. It has robust evidence for both glycaemic control and weight reduction, as well as cardiovascular benefit in high‑risk patients.

Nevolat must be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the product. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 days, then return to refrigeration as soon as possible.

Nevolat is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection is performed using a pre‑filled pen or syringe, following the technique and site‑rotation guidelines provided by the prescriber or product label.

Serious adverse events include acute pancreatitis, gallbladder disease, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), and, based on animal data, a potential risk of thyroid C‑cell tumours. Patients should seek immediate medical attention for persistent abdominal pain, severe nausea, or signs of an allergic reaction.

Nevolat is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in patients with known hypersensitivity to liraglutide or any excipients. Caution is also advised for those with severe renal impairment or a history of pancreatitis.